Movement Alert｜BEONE MEDICINES Rises 3.58% in Regular Trading, JPMorgan Increases Stake to 9.05% Amid Strong Half-Year Results

Market Focus08-20 09:34

On August 20, BEONE MEDICINES rose 3.58% in regular trading, reaching HK$230.6 per share, with turnover of HK$122 million.

On the news front, JPMorgan Chase purchased 4.1197 million shares on August 11 at an average price of HK$219.79 per share, investing approximately HK$905 million and raising its stake from 8.77% to 9.05%. Meanwhile, the company reported robust first-half results with total revenue of RMB 22.22 billion, up 26.8% year-over-year, and net profit attributable to shareholders of RMB 3.271 billion, surging 627.1% year-over-year, driven by global commercialization of its flagship product Brukinsa.

Multiple institutions have recently raised target prices, with CLSA upgrading to HK$321.7, BOCOM International to HK$276, and CICC maintaining HK$266, all with Buy or Outperform ratings. The company's audit committee is scheduled to review interim results on August 26, with market expectations remaining positive ahead of the formal earnings confirmation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153170752?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-20 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153170752","market":"hk","top_or_hot":-1,"title":"Movement Alert｜BEONE MEDICINES Rises 3.58% in Regular Trading, JPMorgan Increases Stake to 9.05% Amid Strong Half-Year Results","media":"Market Focus","content":"<p><p>On August 20, BEONE MEDICINES rose 3.58% in regular trading, reaching HK$230.6 per share, with turnover of HK$122 million.</p><p>On the news front, JPMorgan Chase purchased 4.1197 million shares on August 11 at an average price of HK$219.79 per share, investing approximately HK$905 million and raising its stake from 8.77% to 9.05%. Meanwhile, the company reported robust first-half results with total revenue of RMB 22.22 billion, up 26.8% year-over-year, and net profit attributable to shareholders of RMB 3.271 billion, surging 627.1% year-over-year, driven by global commercialization of its flagship product Brukinsa.</p><p>Multiple institutions have recently raised target prices, with CLSA upgrading to HK$321.7, BOCOM International to HK$276, and CICC maintaining HK$266, all with Buy or Outperform ratings. The company's audit committee is scheduled to review interim results on August 26, with market expectations remaining positive ahead of the formal earnings confirmation.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BEONE MEDICINES Rises 3.58% in Regular Trading, JPMorgan Increases Stake to 9.05% Amid Strong Half-Year Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BEONE MEDICINES Rises 3.58% in Regular Trading, JPMorgan Increases Stake to 9.05% Amid Strong Half-Year Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-20 09:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 20, BEONE MEDICINES rose 3.58% in regular trading, reaching HK$230.6 per share, with turnover of HK$122 million.</p><p>On the news front, JPMorgan Chase purchased 4.1197 million shares on August 11 at an average price of HK$219.79 per share, investing approximately HK$905 million and raising its stake from 8.77% to 9.05%. Meanwhile, the company reported robust first-half results with total revenue of RMB 22.22 billion, up 26.8% year-over-year, and net profit attributable to shareholders of RMB 3.271 billion, surging 627.1% year-over-year, driven by global commercialization of its flagship product Brukinsa.</p><p>Multiple institutions have recently raised target prices, with CLSA upgrading to HK$321.7, BOCOM International to HK$276, and CICC maintaining HK$266, all with Buy or Outperform ratings. The company's audit committee is scheduled to review interim results on August 26, with market expectations remaining positive ahead of the formal earnings confirmation.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1153170752","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153170752","pubTimestamp":1787189667,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 20, BEONE MEDICINES rose 3.58% in regular trading, reaching HK$230.6 per share, with turnover of HK$122 million.On the news front, JPMorgan Chase purchased 4.1197 million shares on August...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"走势提醒|BEONE MEDICINES 常规交易中上涨 3.58%，摩根大通在强劲的半年业绩中增持至 9.05%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On August 20, BEONE MEDICINES rose 3.58% in regular trading, reaching HK$230.6 per share, with turnover of HK$122 million.On the news front, JPMorgan Chase purchased 4.1197 million shares on August 11 at an average price of HK$219.79 per share, investing approximately HK$905 million and raising its stake from 8.77% to 9.05%. Meanwhile, the company reported robust first-half results with total revenue of RMB 22.22 billion, up 26.8% year-over-year, and net profit attributable to shareholders of RMB 3.271 billion, surging 627.1% year-over-year, driven by global commercialization of its flagship product Brukinsa.Multiple institutions have recently raised target prices, with CLSA upgrading to HK$321.7, BOCOM International to HK$276, and CICC maintaining HK$266, all with Buy or Outperform ratings. The company's audit committee is scheduled to review interim results on August 26, with market expectations remaining positive ahead of the formal earnings confirmation.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153170752","isCrawlerRequest":true}